@WSJ Plz Cover #DES Shame in @lillypad Annual Report #Lilly #LLY #keepLillyhonest

30 Mar

From Pgs 79-80 – Note DES Info has put important quotes in BOLD.

United States Securities and Exchange Commission, Washington, D.C. 20549

Form 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2012

Commission file number 001-06351

Eli Lilly and Company

Note 15: Contingencies

We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as specifically noted below with respect to the Alimta Hatch-Waxman Act patent challenges, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.

Diethylstilbestrol Product Liability Litigation

In approximately 90 U.S. lawsuits against us involving approximately 90 claimants, plaintiffs seek to recover damages on behalf of children or grandchildren of women who were prescribed diethylstilbestrol (DES) during pregnancy in the 1950s and 1960s. Approximately 80 of these claimants allege that they were indirectly exposed in utero to the medicine and later developed breast cancer as a consequence. We believe these claims are without merit and are prepared to defend against them vigorously.

Product Liability Insurance

Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims in the future. In the past several years, we have been unable to obtain product liability insurance due to a very restrictive insurance market. Therefore, for substantially all of our currently marketed products, we have been and expect that we will continue to be completely self-insured for product liability losses. The DES claims are covered by insurance, subject to deductibles and coverage limits. There is no assurance that we will be able to fully collect from our insurance carriers in the future.


DES In Today’s Huffington Post!

13 Mar

Terrific piece in today’s Huffington Post that ties DES to the World Health Organization’s recent “global threat” announcement about hormone-mimicking chemicals:




Latest Clarifications

11 Mar

As you all know, DES Info strives to get you info as soon as possible. Sometimes the info we receive from our sources is a little “off” — but at least we’re trying to share news with you. It beats silence every time.

Below are two clarifications about today’s hearing:

* Aaron Levine, lead attorney for the plaintiffs, and Julie Oliver-Zhang made the motion for the trial to take place on June 25. We will know next week whether that motion has been granted.

* The trial will take place in Boston before Judge Bowler.

Thank you!

Motion for Trial on June 25! #KeepLillyHonest

11 Mar

Eli Lilly refused to mediate. Aaron Levine, lead attorney for the plaintiffs, and Julie Oliver-Zhang moved for expedited trial for 4 women from New York. If the motion is granted, the trial will take place before Judge Bowler on June 25 in Boston.

About the March 11 DES Breast Cancer Hearings in Boston

10 Mar
The latest briefs, which are publicly filed, show that the defendants want to now officially ditch the case management order regarding the good faith mediation agreement while plaintiffs are seeking to enforce the original agreement with Eli Lilly and other drug companies to continue to mediate. Defendants have proposed a new case management order that contemplates 50 some trials that will take years to resolve. Nevertheless, Judge Bowler has continued to order mediation between the parties, which will take place on March 11, 2013. Plaintiffs have moved to consolidate 4 separate DES daughter plaintiffs from New York for an expedited trial date in Summer of 2013. The decision to consolidate will likely be discussed during the March 11th meeting.

Even though the plaintiffs won the Daubert hearing in January of 2012 and the first DES breast cancer case with the four Fecho sisters settled at trial, Defendant Eli Lilly continues to claim that these cases are “without merit” in their 10-K shareholder documents. http://investor.lilly.com/secfiling.cfm?filingID=59478-13-7&CIK=59478

Would You Like To Ask Eli Lilly A Question?

8 Mar

Just a thought… how many of you would like to join Eli Lilly’s free webinar…

Next Tuesday March 12 eyeforpharma are hosting a free webinar called ‘How Lilly Makes Multichannel Work’.

A marketing executive from Lilly, together with their solution provider, will explain their methodology and results, highlighting lessons learned and in particular the benefits from focussing on an internal strategy before attempting to look externally. You’ll also be able to ask questions to them directly.

The webinar takes place next Tuesday (March 12th) and you can register here:

Even if you’re not free that day, do sign up and I’ll send you the recording afterwards. Also please offer the above link to any colleagues who might like to attend.

Thank you and see you there…


Paul Simms

A DES Son Speaks Out

7 Mar

Read this very informative piece here: http://ireport.cnn.com/docs/DOC-938285